EPISODE · Mar 10, 2022 · 26 MIN
Harnessing a Natural Mechanism to Silence Disease
from RARECast
RNA interference offers the potential disrupt the translation of instructions from genes with mutations into proteins that drive diseases. Silence Therapeutics is developing a pipeline of therapies based on its mRNAi Gold platform that allows it to target short interfering RNAs to liver cells. We spoke to Mark Rothera, who at the time served as CEO of Silence Therapeutics and Giles Campion, Silence’s chief medical officer and head of R&D, about the company’s platform technology, why it can be used to target a broad range of genetic diseases, and the company’s programs in development. Since recording this podcast, Rothera stepped down as CEO and the company named Craig Tooman, who had served as CFO of the company since January 2021, as its new president and CEO.
Embed this episode
What this episode covers
Mark Rothera, who at the time served as CEO of Silence Therapeutics and Giles Campion, Silence’s chief medical officer and head of R&D, discuss the company’s platform technology, why it can be used to target a broad range of genetic diseases, and the company’s programs in development.
NOW PLAYING
Harnessing a Natural Mechanism to Silence Disease
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.